



Targovax to present at forthcoming Life Science and Investor conferences

Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:

INVESTOR/PARTNERING CONFERENCES

Sachs Associates 9th Annual ELSCEO Forum & Exhibition

Zurich, 15 March, 2016

Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)

Presentation time: 10:45

Venue: Hilton Zurich Airport Hotel

BIO-EUROPE Spring 2016

Stockholm, 5-6 April, 2016

Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)

BioEquity

Copenhagen, 10-11 May, 2016

Participants: Gunnar Gårdemyr (CEO), Øystein Soug (CFO) and Magnus Jäderberg (CMO)

BIO International Convention

San Francisco, 6-9 June, 2016

Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)

SCIENTIFIC CONFERENCES

Royal Swedish Academy of Engineering Sciences

Stockholm, 16 May, 2016

Participants: Magnus Jäderberg (CMO)

ASCO

Chicago, 3-7 June, 2016

Participants: Magnus Jäderberg (CMO)

The Presentations will be available to download at targovax.com/investors/presentations following the event.

For further information, please contact:

Gunnar Gårdemyr

CEO

Phone: +41 798 340 585

Email: ggardemyr@targovax.com

Øystein Soug

CFO

Phone: +47 906 56 525

Email: oystein.soug@targovax.com